Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corline Biomedical AB Days Payable Historical Data
* Premium members only.
The historical data trend for Corline Biomedical AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IZ7 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Corline Biomedical AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corline Biomedical AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Corline Biomedical AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Corline Biomedical AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corline Biomedical AB (FRA:IZ7) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Corline Biomedical AB and its competitors. Over the past decade, Corline Biomedical AB's Days Payable has ranged from 446.36 to 1,395.33. According to the industry distribution chart, Corline Biomedical AB ranks #155 out of 701 companies in the Biotechnology industry, placing it in the top 22.1%.
Is Corline Biomedical AB's Days Payable too high?
Corline Biomedical AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 446.36 to a high of 1,395.33. Based on the distribution chart, Corline Biomedical AB ranks #155 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corline Biomedical AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Corline Biomedical AB ranks #155 out of 701 companies for Days Payable. This places Corline Biomedical AB in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Historically, Corline Biomedical AB's own Days Payable has ranged from 446.36 to 1,395.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Corline Biomedical AB and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corline Biomedical AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Corline Biomedical AB (FRA:IZ7) has a current Days Payable of 0.00. The stock's GF Value™ is €0.45, compared to a current price of €1.55 — trading 243.3% above its estimated fair value. The current Days Payable is 0.00. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Corline Biomedical AB (FRA:IZ7), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?
Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued.
The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.
Key valuation signals for FRA:IZ7:
Days Payable: 0.00
GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score
Get the complete analysis for FRA:IZ7
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IZ7 has been successfully added to your 
